newsimageFarmalider, a pharmaceutical company that specializes in innovating with molecules that have lost their patent, has taken another step in its globalization by opening a new office in Miami (USA). This latest location expands on those the company already has in Barcelona (Spain), Istanbul (Turkey) and Auckland (New Zealand). The growth plan began eight years ago. Farmalider’s Turkish subsidiary is now the group’s most profitable location. By bringing Miami into the picture, Farmalider hopes it will provide a springboard into the Latin America market where, as Chairman José Luis Berenguer states, “We have created partnerships with several companies in order to diversify risk.”

As well as going global, one of Farmalider’s short-term aims is to float on the London Alternative Investment market (AIM). “In the United Kingdom, this is a very important market and includes over 1500 more relevant companies. Nobody who has been around for 25 years enters the Spanish Alternative Stock Market (MAB), which is made up of smaller companies. MAB investors are looking for risk and we are not a risky company, so the MAB didn’t fit the bill for us,” Berenguer explains.

Today, Farmalider is comprised of 14 companies. The newest are Ophta Pharma and Ophta Biotech—ophthalmology and intraocular contact lens specialists—for which Farmalider is now seeking to bring in an international pharmaceuticals company to optimize sales.